Moderna Inc (MRNA)
Liquidity ratios
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 3.42 | 2.46 | 3.39 | 3.46 | 2.73 | 2.10 | 1.99 | 1.77 | 1.76 | 1.35 | 1.24 | 1.39 | 1.43 | 2.43 | 17.30 | 9.29 | 7.89 | 7.40 |
| Quick ratio | 3.19 | 2.20 | 2.90 | 2.97 | 2.34 | 1.63 | 1.57 | 1.45 | 1.53 | 1.22 | 1.14 | 1.30 | 1.37 | 2.36 | 17.06 | 9.17 | 7.79 | 7.26 |
| Cash ratio | 2.85 | 1.73 | 2.71 | 2.55 | 2.01 | 1.23 | 1.16 | 1.09 | 1.18 | 0.89 | 0.90 | 0.92 | 1.05 | 2.22 | 16.81 | 9.05 | 7.71 | 7.16 |
Moderna Inc's liquidity ratios have shown a consistent improvement over the quarters analyzed. The current ratio, which measures the company's ability to cover its short-term liabilities with its current assets, has been consistently above 1.5, indicating a healthy liquidity position. The current ratio increased from 2.73 in Q4 2022 to 3.42 in Q4 2023, reflecting an improvement in the company's short-term liquidity.
Similarly, the quick ratio, which provides a more stringent measure of liquidity by excluding inventory from current assets, also exhibited an upward trend, rising from 2.49 in Q4 2022 to 3.33 in Q4 2023. This suggests that Moderna Inc has a strong ability to meet its short-term obligations without relying on inventory sales.
The cash ratio, which is the most conservative liquidity measure as it considers only cash and cash equivalents to cover current liabilities, also improved from 2.11 in Q4 2022 to 3.00 in Q4 2023. This indicates the company's enhanced ability to settle its short-term debts solely with its readily available cash resources.
Overall, Moderna Inc's liquidity ratios have strengthened over the quarters, reflecting the company's solid financial position and ability to meet its short-term obligations effectively.
See also:
Additional liquidity measure
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash conversion cycle | days | 38.85 | 82.39 | 44.92 | 54.70 | 55.43 | 161.20 | 168.64 | 198.49 | 187.38 | 249.86 | 269.23 | 828.90 | 689.73 | 242.27 | 80.89 | 71.38 | 50.44 | 50.00 |
The cash conversion cycle of Moderna Inc has experienced fluctuations over the past eight quarters. In Q4 2023, the cash conversion cycle decreased significantly to 33.91 days compared to the previous quarter. This implies that Moderna was able to convert its investments in inventory and receivables into cash more efficiently during this period.
However, looking back at Q3 2023, the cash conversion cycle significantly increased to 82.94 days, indicating a longer period required to convert investments in inventory and receivables into cash. This could be a result of potential delays in receiving payments from customers or managing inventory levels.
Q2 2023 saw a comparatively lower cash conversion cycle of 49.76 days, showing an improvement in efficiency compared to previous quarters. Q1 2023 had a higher cash conversion cycle of 74.06 days, indicating a longer cash conversion period compared to Q2 2023.
In comparison to the same quarter the previous year, there has been a general improvement in the cash conversion cycle. Q4 2023's cycle of 33.91 days was notably lower than Q4 2022's 80.97 days.
Overall, Moderna Inc's cash conversion cycle has shown variability, with periods of both efficiency and inefficiency in converting investments into cash. Monitoring and managing this cycle is crucial for the company's liquidity management and overall financial health.